Rapid induction of apoptosis in prostate cancer cells by selenium: Reversal by metabolites of arachidonate 5-lipoxygenase

Biochemical and Biophysical Research Communications

Volumn 315, Issue 3, 2004, Pages 624-635

  Ghosh, Jagadananda ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

5(S) Hydroxyeicosatetraenoic acid; 5 Lipoxygenase; Apoptosis; Arachidonic acid; Chemoprevention; Prostate cancer; Selenium

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; ANTINEOPLASTIC AGENT; ARACHIDIC ACID; ARACHIDONATE 5 LIPOXYGENASE; SODIUM SELENITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL ASSAY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME METABOLISM; HUMAN; HUMAN CELL; METABOLITE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TARGET CELL DESTRUCTION;

EID: 1242295294     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.01.100     Document Type: Article

References (56)

1. Greenwald P., Milner J.A., Anderson D.E., McDonald S.S. Micronutrients in cancer chemoprevention. Cancer Metastasis Rev. 21:2002;217-230.
2. Pathak S.K., Sharma R.A., Mellon J.K. Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review). Int. J. Oncol. 22:2003;5-13.
3. Combs G.F. Impact of selenium and cancer-prevention findings on the nutrition-health paradigm. Nutr. Cancer. 40:2001;6-11.
4. DePrimo S.E., Shinghal R., Vidanes G., Brooks J.D. Prevention of prostate cancer. Hematol. Oncol. Clin. North Am. 15:2001;445-457.
5. Klein E.A., Thompson I.M., Lippman S.M., Goodman P.J., Albanes D., Taylor P.R., Coltman C. SELECT: the next prostate cancer prevention trial. Selenium and vitamin E cancer prevention trial. Urol. Oncol. 21:2003;59-65.
6. Clarck L.C., Combs G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., Davis L.S., Glover R.A., Graham G.F., Gross E.G., Krongrad A., Lesher J.L., Park H.K., Sanders B.B., Smith C.L., Taylor J.R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA. 276:1996;1957-1963.
7. Yoshizawa K., Willet W.C., Morris S.J., Stampfer M.J., Spiegelman D., Rimm E.B., Giovannucci E. A study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Natl. Cancer Inst. 90:1998;1219-1224.
8. Helzlsouer K.J., Huang H.Y., Alberg A.J., Hoffman S., Burke A., Norkus E.P., Morris J.S., Comstock G.W. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J. Natl. Cancer Inst. 92:2000;2018-2023.
9. Nomura A.M., Lee J., Stemmermann G.N., Combs G.F. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9:2000;883-887.
10. Brooks J.D., Metter E.J., Chan D.W., Sokol L.J., Landis P., Nelson W.G., Muller D., Andres R., Carter H.B. Plasma selenium level before diagnosis and the risk of prostate cancer development. J. Urol. 166:2001;2034-2038.
11. Goodman G.E., Schaffer S., Bankson D.D., Highes M.P., Omenn G.S. Carotene and retinol efficacy trial co-investigators, Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 10:2001;1069-1076.
12. Burk R.F. Selenium, an antioxidant nutrient. Nutr. Clin. Care. 5:2002;75-79.
13. Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. Free Radic. Biol. Med. 27:1999;951-965.
14. Kim Y.S., Milner J. Molecular targets for selenium in cancer prevention. Nutr. Cancer. 40:2001;50-54.
15. Venkateswaran V., Klotz L.H., Fleshner N.E. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res. 62:2002;2540-2555.
16. Jiang C., Wang Z., Ganther H., Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol. Cancer Ther. 1:2002;1059-1066.
17. Redman C., Scott J.A., Baines A.T., Basye J.L., Clark L.C., Calley C., Roe D., Payne C.M., Nelson M.A. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 125:1998;103-110.
18. Menter D.G., Sabichi A.L., Lippman S.M. Selenium effects on prostate cell growth. Cancer Epidemiol. Biomarkers Prev. 9:2000;1171-1182.
19. Zhong W., Oberley T.D. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res. 61:2001;7071-7078.
20. Fleming J., Ghose A., Harrison P.R. Molecular mechanisms of cancer prevention by selenium compounds. Nutr. Cancer. 40:2001;42-49.
21. Ghose A., Fleming J., El-Bayoumy K., Harrison P.R. Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compounds: involvement of mitogen-activated protein kinase and Fas pathways. Cancer Res. 61:2001;7479-7487.
22. Powis G., Gasdaska J.R., Gasdaska P.Y., Berggren M., Kirkpatrick D.L., Engman L., Cotgreave I.A., Angulo M., Baker A. Selenium and the thioredoxin redox system: effects on cell growth and death. Oncol. Res. 9:1997;303-312.
23. Shen H., Yang C., Liu J., Ong C.N. Dual role of glutathione in selenite-induced oxidative stress and apoptosis in human hepatoma cells. Free Radic. Biol. Med. 28:2000;1115-1124.
24. Fang Y.Z., Yang S., Wu G. Free radicals, antioxidants, and nutrition. Nutrition. 18:2002;872-879.
25. Chen C.J., Huang H.S., Lin S.B., Chang W.C. Regulation of cyclooxygenase and 12-lipoxygenase catalysis by phospholipid hydroperoxide glutathione peroxidase in A431 cells. Prostaglandins Leukot. Essent. Fatty Acids. 62:2000;261-268.
26. Schnurr K., Belkner J., Ursini F., Schewe T., Kuhn H. The selenoenzyme phospholipid hydroperoxide glutathione peroxidase controls the activity of the 15-lipoxygenase with complex substrates and preserves the specificity of the oxygenation products. J. Biol. Chem. 271:1996;4653-4658.
27. Weitzel F., Wendel A. Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone. J. Biol. Chem. 268:1993;6288-6292.
28. Werz O., Steinhilber D. Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells: the presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. Eur. J. Biochem. 242:1996;90-97.
29. Straif D., Werz O., Kellner R., Bahr U., Steinhilber D. Glutathione peroxidase-1 but not -4 is involved in the regulation of cellular 5-lipoxygenase activity in monocytic cells. Biochem. J. 349:2000;455-461.
30. Hammarberg T., Kuprin S., Radmark O., Holmgren A. EPR investigation of the active site of recombinant human 5-lipoxygenase: inhibition by selenide. Biochemistry. 40:2001;6371-6378.
31. Bjornstedt M., Odlander B., Kuprin S., Claesson H.E., Holmgren A. Selenite incubated with NADPH and mammalian thioredoxin reductase yields selenide, which inhibits lipoxygenase and changes the electron spin resonance of the active site iron. Biochemistry. 35:1996;8511-8516.
32. Chaudry A.A., Wahle K.W., McClinton S., Moffat L.E. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int. J. Cancer. 57:1994;176-180.
33. Dahiya R., Yoon W.H., Boyle B., Schoenberg S., Yen T.S., Narayan P. Biochemical, cytogenetic and morphological characteristics of human primary and metastatic prostate cancer cell lines. Biochem. Int. 27:1992;567-577.
34. Anderson K.M., Wygodny J.B., Ondrey F., Harris J. Human PC-3 prostate cell line DNA synthesis is suppressed by eicosatetraenoic acid, an in vitro inhibitor of arachidonic acid metabolism. Prostate. 12:1988;3-12.
35. Glasgow W.C., Afshari C.A., Barrett J.C., Eling T.E. Modulation of the epidermal growth factor mitogenic response by metabolites of linoleic and arachidonic acid in Syrian hamster embryo fibroblasts. Differential effects in tumor suppressor gene (+) and (-) phenotypes. J. Biol. Chem. 267:1992;10771-10779.
36. Peppelenbosch M.P., Tertoolen L.G., Hage W.J., de Laat S.W. Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cell. 74:1993;565-575.
37. Liu P., Wen M., Hayashi J. Characterization of ATP receptor responsible for the activation of phospholipase A2 and stimulation of prostaglandin E2 production in thymic epithelial cells. Biochem. J. 308:1995;399-404.
38. Dethlefsen S.M., Shepro D., D'Amore P.A. Arachidonic acid metabolites in bFGF-, PDGF-, and serum-stimulated vascular cell growth. Exp. Cell Res. 212:1994;262-273.
39. Ghosh J., Myers C.E. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. 235:1997;418-423.
40. Ghosh J., Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. USA. 95:1998;13182-13187.
41. Ghosh J., Myers C.E. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv. Exp. Med. Biol. 469:1999;577-582.
42. Ghosh J. Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem. Biophys. Res. Commun. 307:2003;342-349.
43. Ghosh J., Myers C.E. Molecular mechanisms of prostate cancer cell death triggered by inhibition of arachidonate 5-lipoxygenase: involvement of Fas death receptor-mediated signals. Adv. Exp. Med. Biol. 507:2002;415-420.
44. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
45. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687.
46. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 6:2000;513-519.
47. Belmokhtar C.A., Hillion J., Dudognon C., Fiorentino S., Flexor M., Lanotte M., Ségal-Bendirdjian E. Apoptosome-independent pathway for apoptosis: biochemical analysis of Apaf-1 defects and biological outcomes. J. Biol. Chem. 278:2003;29571-29580.
48. Borner C., Monney L. Apoptosis without caspases: an inefficient molecular guillotine? Cell Death Diff. 6:1999;497-507.
49. Ford-Hutchinson A.W., Gresser M., Young R.N. 5-Lipoxygenase. Ann. Rev. Biochem. 63:1994;383-417.
50. Ancil R.J., Takahashi Y., Kibune Y., Campbell R., Smith J.R. Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis. J. Intern. Med. Res. 18:1990;75-88.
51. He Q., Rashid A., Rong R., Hillman M.J., Huang Y., Sheikh M.S. Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol. Ther. 1:2002;287-290.
52. Haluska P.V., Mais D.E., Mayeux P.R., Morinelli T.A. Thromboxane, prostaglandin and leukotriene receptors. Ann. Rev. Pharmacol. Toxicol. 10:1989;213-239.
53. Smith W.L. The eicosanoids and their biochemical mechanisms of action. Biochem. J. 259:1989;315-324.
54. O'Flaherty J.T., Rogers L.C., Chadwell B.A., Owen J.S., Rao A., Cramer S.D., Daniel L.W. 5(S)-Hydroxy-6, 8, 11, 14-E,Z,Z,Z-eicosatetraenoate stimulates PC3 cell signaling and growth by a receptor-dependent mechanism. Cancer Res. 62:2002;6817-6819.
55. Hosoi T., Koguchi Y., Sugikawa E., Chikada A., Ogawa K., Tsuda N., Suto N., Tsunoda S., Taniguchi T., Ohnuki T. Identification of a novel human eicosanoid receptor coupled to Gi/o. J. Biol. Chem. 277:2002;31459-31465.
56. Kolonel L.N., Nomura A.M., Cooney R.V. Dietary fat and prostate cancer: current status. J. Natl. Cancer Inst. 91:1999;414-428.